Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immunocore Holdings PLC

IMCR ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$31.73

▲ +2.39%

Market Cap $1.66B · Vol 128.90K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.66B

Small Cap

Div Yield

N/A

EPS Growth

+78.07%

YoY

RSI (14)

46.16

Momentum

Beta

0.79

vs Market

52W High

$40.41

21.48% below

52W Low

$27.60

14.96% above

Volume

128.90K

Avg 125.39K

P/B

4.62

Price-to-book

ROE

-9.58%

Return on equity

Free Float

99.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Immunocore Holdings PLC (IMCR) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMCR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.51%

+7.96%

-6.68%

+7.27%

YTD

-8.59%

-5.28%

-36.78%

-18.99%

Financials & Valuation

TTM · Annual

Total Revenue	$400.02M
Net Income	$-35,514,000.00
Revenue Growth (YoY)	-1.42%
Gross Margin	98.73%
Operating Margin	-11.34%
Net Profit Margin	-8.88%
ROE	-9.58%
ROA · ROIC	-1.84% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	4.37
P/B	4.62
P/FCF	N/A
EPS Growth	+78.07%
Outstanding Shares	51.68M

Technical Indicators

50-Day SMA	$31.54
200-Day SMA	$31.64
RSI (14)	46.16
Beta	0.79
52-Week High	$40.41
52-Week Low	$27.60

Volume Today	128.90K
Avg Daily Volume (30D)	125.39K
Relative Volume	1.03x
Volatility (10D)	58.27
Volatility (30D)	48.84
Free Float	99.00%

Analyst Consensus

BUY

Current Price $31.73

Mean Target $66.36

52W Low$27.60 52W High$40.41

Current

Target

$27.60 $40.41

Current Analyst target

+109.15% upside potential · 12 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00YYCXG54

ISINUS45258D1054

CountryUK

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +4.28% JNJ Johnson & Johnson +2.13% ABBV AbbVie Inc. +0.68% NVS Novartis AG +0.70% NOVN.S Novartis AG +0.29%

Company Profile

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.